Anti-BCMA/CD3 Bispecific Monoclonal Antibody clinical trials
How each study uses Anti-BCMA/CD3 Bispecific Monoclonal Antibody is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-BCMA/CD3 Bispecific Monoclonal Antibody studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2025 | 1 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 6
Institute of Hematology & Blood Diseases Hospital, China (4) · West China Hospital (1) · Turun Song (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test Anti-BCMA/CD3 Bispecific Monoclonal Antibody.
- Dec 2026BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed AmyloidosisPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
- Jul 2027CM336-SOC for Dynamically High-Risk Multiple Myeloma StudyPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
- Oct 2027Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple MyelomaPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
Studies
Open first, then newest update. How each study uses Anti-BCMA/CD3 Bispecific Monoclonal Antibody is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple MyelomaNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07789522Written as anti-BCMA/CD3 bispecific antibodyHow we know
- CM336-SOC for Dynamically High-Risk Multiple Myeloma StudyNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07648459Written as anti-BCMA/CD3 bispecific antibodyHow we know
- MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple MyelomaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07409454Written as anti-BCMA/CD3 bispecific antibodyHow we know
- Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) in Kidney Transplant Recipients With Chronic Active Antibody-Mediated RejectionRecruitingPhase 4Turun SongNCT07689578Written as BiTE (BCMA x CD3 Bispecific Antibody)How we know
- BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed AmyloidosisRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07151690Written as anti-BCMA/CD3 bispecific antibodyHow we know
- Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates With cPRA ≥ 90%Not yet recruitingPhase 4West China HospitalNCT07689149Written as BiTE (BCMA x CD3 Bispecific Antibody)How we know